The success of incretin-based therapies for T2D [7] and recent advances in our understanding of mechanisms for nutrient sensing [8]–[10] suggest that nutrient-based agents may hold potential for future anti-T2D drug development. The gene discussed is GCG; the disease is type 2 diabetes mellitus.